Skip to main content

Table 2 Baseline demographics and comorbidities

From: The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis

  Newly diagnosed ATTRv Amyloidosis patients N = 141 Matched controlsa N = 423 p value
Age, year, mean (SD) 62.5 (14.3) 62.5 (14.2) n/ad
 18–34, n (%) 6 (4.3) 18 (4.3)  
 35–54 27 (19.1) 81 (19.1)  
 55–64 52 (36.9) 156 (36.9)  
 65+ 56 (39.7) 168 (39.7)  
Female, n (%) 76 (53.9) 228 (53.9) n/ad
Region, n (%)
 Midwest 26 (18.4) 78 (18.4) n/ad
 Northeast 47 (33.3) 141 (33.3)  
 South 55 (39.0) 165 (39.0)  
 West 13 (9.2) 39 (9.2)  
Insurance type, n (%)b    0.087
 PPO/POS 99 (70.2) 239 (56.5)  
 HMO/EPO 8 (5.7) 30 (7.1)  
 CDHP/HDHP 14 (9.9) 72 (17.0)  
 Comprehensive 20 (14.2) 80 (18.9)  
Charlson comorbidity index, mean (SD) 2.7 (3.0) 1.1 (1.9) < 0.001
Number of chronic conditions, mean (SD) 5.1 (2.7) 3.2 (2.3) < 0.001
Health care provider, n (%)    0.018
 Primary care 65 (46.1) 230 (54.4)  
 Cardiologist 5 (3.5) 10 (2.4)  
 Dermatologist 4 (2.8) 16 (3.8)  
 Gastroenterologist 6 (4.3) 6 (1.4)  
 Neurologist 6 (4.3) 2 (0.5)  
 Rheumatologist 5 (3.5) 6 (1.4)  
 Otherc/unknown 50 (35.5) 153 (36.2)  
  1. ATTRv hereditary transthyretin, CDHP/HDHP consumer directed health plan/high deductible health plan, EPO exclusive provider organization, HMO health maintenance organization, PPO/POS preferred provider organizations/point of service
  2. aMatched with age, gender, and region
  3. bTwo matched controls had missing/unknown insurance type
  4. cIncludes podiatrists and individual specialties with count < 5
  5. dMatched exactly